When extrapolating these findings to the in vivo situation, we expect that the magnitude of effects of FK866 will be dependent on a tumor-cell’s nutrient state and its capacity for NAD+ synthesis via different metabolic pathways (i.e. via de novo or salvage pathways, via NAPRT or NAMPT). This evidence concerns the gene NAPRT and neoplasm.